[Gene therapy--its present status and future direction].
Remarkable progress in molecular biology has succeeded in developing gene therapy that is applicable in patients with a poor prognosis. At the Annual Meeting of Japanese Pharmacological Society this spring, the symposium entitled "Gene therapy: its present status and future direction" was held and this produced fruitful results. The symposium covered the following five topics, introduction to gene therapy, ischemic diseases, intractable heart failure, metastatic long cancer, ADA deficiency, which were presented by Drs. Y. Kaneda, Osaka Univ.; M. Aoki, Osaka Univ.; T. Kawada, Niigata Univ.; T. Fujiwara, Okayama Univ. and Y. Sakiyama, Hokkaido Univ., respectively.
Toyooka
T
T
Department of Cardiovascular Medicine, University of Tokyo, Japan.
D000243:Adenosine Deaminase / Q000172:deficiency; D000818:Animals; D006224:Cricetinae; D003598:Cytoskeletal Proteins / Q000235:genetics; D004195:Disease Models, Animal; D005544:Forecasting; D016158:Genes, p53; D015316:Genetic Therapy / Q000639:trends*; D006333:Heart Failure / Q000628:therapy; D019382:Human Growth Hormone / Q000235:genetics; D006801:Humans; D008562:Membrane Glycoproteins / Q000235:genetics; D017202:Myocardial Ischemia / Q000628:therapy; D009369:Neoplasms / Q000628:therapy; D049031:Sarcoglycans
D003598:Cytoskeletal Proteins; D008562:Membrane Glycoproteins; D049031:Sarcoglycans; D019382:Human Growth Hormone; D000243:Adenosine Deaminase